0.05Open0.05Pre Close0 Volume2.04K Open Interest30.00Strike Price0.00Turnover572.53%IV872.49%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0515Delta0.0324Gamma61.80Leverage Ratio-0.0129Theta0.0000Rho3.18Eff Leverage0.0006Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet